EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Observational studies of inhaled corticosteroid effectiveness in COPD: Lessons learned



Observational studies of inhaled corticosteroid effectiveness in COPD: Lessons learned



Chest: -



Randomized controlled trials at times investigate findings suggested by observational studies. For example, the TORCH trial, which did not show a mortality reduction with inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD), was motivated by some observational studies that suggested considerable reductions in mortality with these drugs. Reasons for these discrepancies are unclear. We searched the literature to identify all observational studies, including cohort and case-control studies, investigating the effectiveness of ICS on major outcomes in COPD patients, including death and hospitalization for COPD. We identified 21 studies and found that nine studies were affected by immortal time bias, five by immeasurable time bias, and seven by the "asthma factor" bias, with some studies by more than one bias. These studies found important reductions in the rates of major COPD outcomes with ICS use, with pooled rate ratios of 0.71 (95% CI 0.67-0.76), 0.76 (95% CI 0.70-0.83) and 0.79 (95% CI 0.73-0.87) respectively for the three sources of bias. In contrast, the five studies unaffected by these major biases did not find an association (pooled rate ratio 1.02; 95% CI: 0.88-1.17). Observational studies are important to provide evidence from real-world data on medication effects. However, appropriate study design and analysis are essential to avoid biases and ensure randomized trials with greater chances of success. The observational studies suggesting potential beneficial effects of non-respiratory drugs to treat COPD, such as statins and beta-blockers, will also need careful review before embarking on long and expensive randomized trials.

(PDF emailed within 0-6 h: $19.90)

Accession: 065365726

Download citation: RISBibTeXText

PMID: 29679596

DOI: 10.1016/j.chest.2018.04.006



Related references

Possible sources of bias in observational studies of the effectiveness of inhaled corticosteroids in COPD. European Respiratory Journal 22(Supplement 43): 9s-12s, September, 2003

Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts. International Journal of Chronic Obstructive Pulmonary Disease 11(): 2341-2348, 2016

Effectiveness and Safety Comparison for Systemic Corticosteroid Therapy With and Without Inhaled Corticosteroids for COPD Exacerbation Management. Annals of PharmacoTherapy: 1060028018777769-1060028018777769, 2018

Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. International Journal of Chronic Obstructive Pulmonary Disease 9(): 1163-1186, 2015

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). Bmj 346(): F3306-F3306, 2013

Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist observational matched cohort study PATHOS. 2013

COPD: an inhaled corticosteroid-resistant, oral corticosteroid-responsive condition. European Respiratory Journal 27(4): 863-865, 2006

What have we learned from observational studies and clinical trials of mild to moderate COPD?. Respiratory Research 19(1): 177-177, 2018

Pathological changes in the COPD lung mesenchyme--novel lessons learned from in vitro and in vivo studies. Pulmonary Pharmacology & Therapeutics 29(2): 121-128, 2015

Incidence of lymphoma associated with underlying lupus: lessons learned from observational studies. Current Opinion in Rheumatology 26(2): 111-117, 2014

Blood Pressure Targets in CKD: Lessons Learned from SPRINT and Previous Observational Studies. Current Cardiology Reports 18(9): 88-88, 2017

Immortal time bias in cohort studies of inhaled corticosteroid effectiveness. European Respiratory Journal 22(Supplement 43): 24s-26s, September, 2003

The utility of observational studies in clinical decision making: lessons learned from statin trials. Postgraduate Medicine 122(3): 222-229, 2010

Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Current Opinion in Rheumatology 26(2): 131-137, 2014

Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 66(8): 699-708, 2011